New Treatment of Common Wart (NCT07543926) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
New Treatment of Common Wart
Egypt70 participantsStarted 2026-04-06
Plain-language summary
this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* \- Age more than or equal to 18 years
* Clinically and dermoscopically confirmed Common warts of both sex
* patient not receiving previous treatment at least one month before recruitment in our study
* Single or multiple lesions suitable for injection.
Exclusion Criteria:
* Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions .
Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
treatment of common wart by PRF injection ( Mild response: < 50% reduction in lesion size , Moderate response: ≥ 50% reduction in lesion size , to measure the change in lesion size , is the patient satisfied or not )
Timeframe: 1 session every 2 weeks for 3 months
2
changes in common warts after treatment by PRF (measuring complete clearance and recurrence of the lesions ,asking about patient satisfaction )